Edition:
United Kingdom

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

22.00USD
21 Jun 2018
Change (% chg)

$-0.30 (-1.35%)
Prev Close
$22.30
Open
$22.20
Day's High
$22.20
Day's Low
$22.00
Volume
10,175
Avg. Vol
191,013
52-wk High
$24.85
52-wk Low
$11.85

Latest Key Developments (Source: Significant Developments)

Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING.  Full Article

Momenta Pharma says Q3 loss per share $0.44
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc -:Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $24.1 million versus $29.1 million.Q3 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.44.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Momenta Pharmaceuticals - co and Mylan are targeting a first regulatory submission for clinical development of M710 by early 2018​.Momenta Pharmaceuticals - ‍updated non-GAAP operating expense guidance of about $200 million - $210 million for 2017 and $43 million - $53 million for Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍expects to recognize $50 million upfront payment from CSL as revenue in Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍estimates that collaborative reimbursement revenues will be approximately $0 - $2 million in Q4 of 2017​.  Full Article

Momenta And Mylan report initial results from phase 1 clinical trial for M834
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc :Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept).Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​.Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​.  Full Article

Mmenta Pharmaceuticals to regain global development and commercialization rights to M923
Tuesday, 27 Sep 2016 

Momenta Pharmaceuticals Inc. : Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire . Agreement to terminate 12 months following notice; Shire will continue to be obligated to fund M923 program till termination . Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire .Co expects top-line results of current phase 3 trial of M923 in late 2016.  Full Article

Momenta Pharmaceuticals reports Q2 loss per share $0.31
Thursday, 4 Aug 2016 

Momenta Pharmaceuticals Inc : Q2 loss per share $0.31 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue $26.4 million versus I/B/E/S view $22.9 million.  Full Article

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE